Preoperative Urinary Retention Increased the Risk of Urinary Retention after Photoselective Vaporization of the Prostate

Sung Yong Cho¹,², Yun Kwan Ro¹, Hwanik Kim¹,², Hwancheol Son¹,²

¹Department of Urology, Seoul National University College of Medicine, ²Department of Urology, SMG-SNU Boramae Medical Center, Seoul, Korea

Purpose: The aim of the present study was to evaluate preoperative acute urinary retention (AUR) as a factor affecting the outcomes of patients who underwent photoselective vaporization of the prostate (PVP), both in terms of overall effectiveness and the postoperative incidence of AUR.

Materials and Methods: Baseline prostate characteristics were obtained for patients who underwent PVP, including prostate-specific antigen (PSA) levels, transrectal ultrasound findings, voiding diary parameters, the International Prostate Symptoms Score (IPSS), and uroflowmetry parameters. These parameters were assessed two weeks, one month, three months, six months, and three years postoperatively. Subjects were divided into AUR and non-AUR groups based on the preoperative occurrence of AUR. Results: Of the 476 patients, 91 had at least one episode of preoperative AUR. The AUR group was found to be significantly older and to have significantly higher PSA levels, lower body mass indices, and larger prostates. At one year of follow-up, the total IPSS was 7.6±6.8 in the AUR group and 11.4±8.2 in the non-AUR group, with the AUR group showing a more significant improvement. In the non-AUR group, 17 of the 385 patients (4.4%) experienced postoperative retention, compared to 16 of the 91 patients (17.6%) patients in the AUR group.

Conclusions: Almost all patients exhibited improvements in subjective and objective voiding parameters following PVP, regardless of the presence of preoperative urinary retention. Patients with a preoperative history of AUR had a higher risk of postoperative retention.

Key Words: Laser therapy; Lower urinary tract symptoms; Prostate; Urinary retention

INTRODUCTION

Benign prostatic hyperplasia (BPH) is highly prevalent in elderly men and is the most common cause of lower urinary tract symptoms (LUTS) [1,2]. BPH is also the most common disorder that reduces men’s quality of life (QoL) [3]. Urinary symptoms from BPH become more frequent with advanced age, and approximately 80% of men in their 70s suffer from BPH-related LUTS [4]. As Korea is quickly becoming an aging society, the incidence of LUTS caused by BPH is expected to rise accordingly. Acute urinary retention (AUR) is a serious and common
complication of BPH that often requires painful emergency urinary drainage via catheterization, directly affecting patients’ QoL. Longstanding or repeated urinary retention can even potentially lead to the development of chronic renal failure [5]. Factors related to AUR include old age, urinary tract infections, low peak urinary flow rate, and large prostate volume [6]. AUR is an indication for surgery, including a reported 25% to 30% of patients undergoing transurethral resection of the prostate [7].

The objective of this study was to retrospectively evaluate the effect of AUR on the outcomes of patients who underwent photovaporization of the prostate (PVP). We also analyzed urodynamic parameters capable of affecting long-term voiding symptoms and QoL in the same cohort, with the goal of improving the preoperative counseling of patients.

MATERIALS AND METHODS

We retrospectively analyzed 476 men who underwent PVP between January 2008 and July 2012. All operations were performed by a single surgeon. The study protocol was approved by the Institutional Review Board of Seoul National University College of Medicine (06-2011-189). The procedure in the present study complies with the Declaration of Helsinki (Edinburgh revision, 2000).

All procedures were performed using a 120-W Green-Light high performance system laser. Medical histories and physical examinations were performed, as well as preoperative evaluations including transrectal ultrasound (TRUS) and multichannel video urodynamics (MMS UD-2000; Medical Measurement System, Enscheded, The Netherlands). Age, serum prostate-specific antigen (PSA), International Prostate Symptom Score (IPSS), maximal flow rate (Qmax), postvoid urine volume (PVR), voiding diary parameters, urodynamic parameters, and surgical methods were analyzed. Data from IPSS, uroflowmetry, and PVR were collected preoperatively and two weeks, one month, three months, six months, and up to three years postoperatively. In some cases, IPSS data were collected through a telephone survey. We only included patients who underwent at least three months of follow-up. Patients who had a preoperative history of AUR and urethral catheterization were categorized into the AUR group. Patients with no history of AUR were categorized into the non-AUR group. Treatment success was defined as improvement in the IPSS score one year postoperatively.

Variables are presented as mean ± standard deviation. All preoperative and postoperative variables were analyzed for statistically significant differences using the independent t-test. Analysis of variance or the paired t-test was used to compare preoperative and postoperative clinical parameters. Logistic regression analysis was used to evaluate predictors of response to treatment. p < 0.05 were considered to indicate statistical significance, and statistical analyses were performed using PASW Statistics ver. 18.0 (IBM Co., Armonk, NY, USA).

RESULTS

Of the 476 patients analyzed, 91 had at least one episode of AUR before undergoing surgery. The mean age of the total population was 68.7 ± 8.6 years and the mean PSA was 5.3 ± 8.9 ng/mL. The mean prostate volume as measured by TRUS was 52.6 ± 33.5 mL. The mean total IPSS was 20.0 ± 8.7, and the mean Qmax was 10.2 ± 7.3 mL/s. The mean PVR was 87.6 ± 120.4 mL. The mean period from the most recent AUR episode to PVP was 10.8 ± 2.9 days. Baseline characteristics according to whether patients had a history of AUR are presented in Table 1. The following urodynamic parameters showed significant differences between the AUR and non-AUR groups: maximal urethral closing pressure (82.9 ± 30.2 cmH₂O vs. 91.8 ± 26.2 cmH₂O; p = 0.014), maximal cystometric capacity (373.0 ± 103.6 mL vs. 403.7 ± 71.7 mL; p = 0.039), detrusor pressure at Qmax (58.8 ± 22.5 cmH₂O vs. 49.1 ± 25.8 cmH₂O; p = 0.011), and the bladder outlet obstruction index (45.5 ± 23.7 vs. 32.5 ± 28.0; p = 0.002).

At one year of follow-up, the mean postoperative IPSS was reduced to 10.8 ± 8.1, and the mean Qmax increased to 16.3 ± 20.0 mL/s. The mean PVR was 34.0 ± 49.5 mL. Statistically significant differences were found between the AUR and non-AUR groups in the following parameters: mean age (71.8 ± 8.9 years vs. 68.0 ± 7.7 years), PSA levels (10.8 ± 14.8 ng/mL vs. 3.9 ± 6.2 ng/mL), body mass index (22.7 ± 3.2 kg/m² vs. 24.2 ± 3.0 kg/m²), and prostate
Table 1. Preoperative characteristics of the patients

| Variable                  | Total         | AUR group     | Non-AUR group | p-value |
|---------------------------|---------------|---------------|---------------|---------|
| Age (yr)                  | 68.7±8.6      | 71.8±8.9      | 68.0±7.7      | <0.05   |
| PSA (ng/dL)               | 5.3±8.9       | 10.8±14.8     | 3.9±6.2       | <0.05   |
| Prostate volume (mL)      | 52.6±33.5     | 69.1±40.9     | 48.9±29.8     | <0.05   |
| Total IPSS                | 20.0±8.7      | 19.9±10.7     | 20.2±8.2      | 0.913   |
| Maximal flow rate (mL/s)  | 10.2±7.3      | 8.7±7.6       | 10.5±7.3      | 0.071   |
| Post-void urine volume (mL)| 87.6±120.4    | 152.9±230.2   | 75.3±81.4     | <0.05   |

Values are presented as mean±standard deviation.
AUR: acute urinary retention, PSA: prostate-specific antigen, IPSS: International Prostate Symptom Score.

Table 2. Mean IPSS and Qmax values at various follow-up durations

| Variable | Preoperative | Follow-up duration |
|----------|--------------|--------------------|
|          | 68.7±8.6     | 71.8±8.9           | 68.0±7.7      |
| PSA      | 5.3±8.9      | 10.8±14.8          | 3.9±6.2       |
| Prostate | 52.6±33.5    | 69.1±40.9          | 48.9±29.8     |
| Total IPSS| 20.0±8.7    | 19.9±10.7         | 20.2±8.2      |
| Maximal flow rate (mL/s)| 10.2±7.3 | 8.7±7.6 | 10.5±7.3 |
| Post-void urine volume (mL)| 87.6±120.4 | 152.9±230.2 | 75.3±81.4 |

IPSS: International Prostate Symptom Score, Qmax: maximal flow rate, AUR: acute urinary retention.

size (69.1±40.9 mL vs. 48.9±29.8 mL), showing that the AUR group was older, had higher PSA levels, lower body mass indices, and larger prostates. No significant differences in voiding diary parameters were observed. Furthermore, the AUR group had longer mean operation times (85.7±50.2 minutes vs. 69.2±45.4 minutes) and lasing times (32.4±18.2 minutes vs. 26.8±24.6 minutes). Uroflowmetry reports in the first two weeks of follow-up showed that the AUR group had lower Qmax values (11.4±5.5 mL/s vs. 14.4±7.8 mL/s) and a higher PVR; however, no significant differences in PVR were observed in later follow-up.

At one year of follow-up, the mean IPSS was 7.6±6.8 in the AUR group and 11.4±8.2 in the non-AUR group, with significantly more improvement observed in the AUR group than in the non-AUR group. Fig. 1 shows changes in the total IPSS from baseline to three years of follow-up, divided into scores for voiding symptoms, storage symptoms, and QoL. Seventeen patients in the non-AUR group (4.4%) and 16 of the 91 (17.6%) patients in the AUR group presented with postoperative AUR. The chi-square test revealed that the AUR group had a 4.6 times higher risk of retention than the non-AUR group.

Multivariate logistic regression analysis showed that old age (>70 years) (odds ratio [OR] = 1.5, 95% confidence interval [CI] = 1.20–1.78), maximal cystometric capacity (OR= 1.1, 95% CI= 1.05–1.35) and a history of AUR (OR= 2.5, 95% CI= 1.89–3.75) were significant predictors of IPSS improvement one year postoperatively, as shown...
DISCUSSION

PVP is one of the surgical treatments available for BPH. Several studies have asserted the efficacy and safety of PVP with a GreenLight laser, including among the Korean male population [8-14]. In 2005, Malek et al [13] reported excellent clinical outcomes involving sustained symptomatic and urodynamic improvements with a minimum necessity for reintervention during a five-year period of postoperative follow-up. In another five-year follow-up study, Hai [14] reported improvement in IPSS, QoL, PVR and Qmax. Our data also showed improvement in clinical parameters in both the AUR and non-AUR groups. Although some differences between these two groups were observed regarding age, PSA, body mass index, and prostate size, immediate and sustained improvements in IPSS, QoL, PVR and Qmax were reported.

At the second postoperative week, the AUR group had significantly lower Qmax and higher PVR values. However, no significant differences were observed in these uroflowmetric parameters on subsequent follow-up visits. This possibly means that patients with preoperative retention require more time to recover than those without preoperative retention. Another interesting point in our study is that the AUR group had better IPSS results than the non-AUR group at one year of follow-up. This suggests that PVP is an efficient method for treating BPH regardless of whether a patient has a history of AUR. Jacobsen et al [6] found that AUR had a direct relationship with LUTS, old age, low Qmax, and enlarged prostate. In our study, the
Table 3. Comparison of urodynamic parameters according to the presence of preoperative AUR

| Variable       | Non-AUR group (n=320) | AUR group (n=68) | p-value |
|----------------|-----------------------|-----------------|---------|
| Qmax (mg/dL)   | 12.5±36.8             | 8.6±4.6         | 0.542   |
| VV (mL)        | 158.9±118.3           | 141.5±116.3     | 0.428   |
| PVR (mL)       | 56.0±73.4             | 90.8±174.9      | 0.227   |
| MUP (cmH2O)    | 91.8±26.2             | 82.9±30.2       | 0.014   |
| MCP (cmH2O)    | 85.6±26.2             | 81.6±43.9       | 0.474   |
| FDV (mL)       | 173.6±82.6            | 167.0±95.3      | 0.755   |
| NDV (mL)       | 253.5±151.3           | 229.5±118.9     | 0.227   |
| SDV (mL)       | 354.2±92.2            | 310.3±101.9     | 0.002   |
| MCC (mL)       | 403.7±71.7            | 373.0±103.6     | 0.039   |
| PdetQmax       | 49.1±25.8             | 58.8±22.5       | 0.011   |
| BOO            | 32.5±28.0             | 45.5±23.7       | 0.002   |
| BCI            | 113.5±80.6            | 93.6±52.6       | 0.090   |

Values are presented as mean±standard deviation. AUR: acute urinary retention, Qmax: maximal flow rate, VV: voided volume, PVR: postvoid urine volume, MUP: maximum urethral pressure, MCP: maximum closure pressure, FDV: first desire to void, NDV: normal desire to void, SDV: strong desire to void, MCC: maximum cystometric capacity, PdetQmax: detrusor pressure at maximum flow rate, BOO: bladder outlet obstruction, BCI: bladder contractility index (PdetQmax−5×Qmax).

same parameters were also found to be associated with the AUR group.

The hemostatic properties of the GreenLight laser stem from the selective absorption of energy in vessels containing hemoglobin with minimal energy propagation through water. Since bleeding can be easily controlled during the operation, operators can obtain a better visual field than in conventional transurethral prostate surgery. The excellent clinical outcomes, low morbidity, technical simplicity, and cost-effectiveness of GreenLight laser PVP have made this technology a valid and efficacious clinical alternative to the conventional transurethral resection of the prostate [15,16]. In our experience, patients undergoing PVP have low complication rates, and the procedure has been found to have remained effective in 60% of patients three years postoperatively [11].

Our analysis of preoperative urodynamic parameters showed that the AUR group had lower maximal urethral closing pressure and maximal cystometric capacity, but higher detrusor pressure at the Qmax and a higher bladder outlet obstruction index. Furthermore, maximal cystometric capacity was a significant predictor in the multivariate logistic regression analysis. Although a higher bladder outlet obstruction index is expected to occur in patients with AUR to some extent, the finding of a lower maximal cystometric capacity was less expected, and may have been due to the fact that AUR patients who were unable to void did not complete the study, and no data on bladder capacity were included [17]. Djavan et al [18] suggested that a history of AUR and low maximal detrusor pressure were the most important factors accounting for a high risk of treatment failure after conventional transurethral resection of the prostate. However, since the detrusor may recover in some patients, the authors recommended prostate surgery in such patients even if preoperative urodynamics suggest an unfavorable outcome. Even though our study did not focus on the treatment failure rate, only three patients with low maximal detrusor pressure (<28 cm of water) exhibited postoperative retention.

This study has several limitations. First, as a retrospective study based on electronic medical records, it was susceptible to bias and dependent on the integrity of the record keeping. Second, the data might have been biased since some of the uroflowmetry measurements were taken during episodes of retention or when the patients complained of voiding difficulty. Lastly, this study did not analyze the use of drugs such as alpha agonists, 5-alpha reductase inhibitors, or anticholinergics. Such drugs might have had an impact on the presence of AUR both preoperatively and postoperatively. However, clinicians prescribed these medications according to the same criteria regardless of the presence of preoperative AUR.

CONCLUSIONS

In this study, almost all patients experienced improvements in subjective and objective voiding parameters following PVP, regardless of the presence of preoperative urinary retention. Patients with a history of AUR had a higher risk of postoperative retention. This information may be useful when counseling patients who are scheduled to undergo PVP operations about their prognosis and further management options.
CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Lee E, Yoo KY, Kim Y, Shin Y, Lee C. Prevalence of lower urinary tract symptoms in Korean men in a community-based study. Eur Urol 1998;33:17-21.
2. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469-71.
3. Jacobsen SJ, Guess HA, Panser L, Girman CJ, Chute CG, Oesterling JE, et al. A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status Among Men. Arch Fam Med 1993;2:729-35.
4. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-9.
5. Rule AD, Lieber MM, Jacobsen SJ. Is benign prostatic hyperplasia a risk factor for chronic renal failure? J Urol 2005;173:691-6.
6. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158:481-7.
7. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989;141:243-7.
8. Kaplan SA, Te AE. Uroflowmetry and urodynamics. Urol Clin North Am 1995;22:309-20.
9. Sandhu JS, Ng C, Vanderbrink BA, Egan C, Kaplan SA, Te AE. High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates. Urology 2004;64:1155-9.
10. Te AE, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO, Hai MA, et al. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. J Urol 2004;172:1404-8.
11. Cho SY, Park S, Jeong MY, Ro YK, Son H. 120W GreenLight High Performance System laser for benign prostate hyperplasia: 68 patients with 3-year follow-up and analysis of predictors of response. Urology 2012;80:396-401.
12. Son H, Song SH, Paick JS. Current laser treatments for benign prostatic hyperplasia. Korean J Urol 2010;51:737-44.
13. Malek RS, Kuntzman RS, Barrett DM. Photoselective potassium-titanyl-phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J Urol 2005;174:1344-8.
14. Hai MA. Photoselective vaporization of prostate: five-year outcomes of entire clinic patient population. Urology 2009;73:807-10.
15. Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, et al; MTOPS RESEARCH Group. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006;175:1422-6.
16. Wosnitzer MS, Rutman MP. KTP/LBO laser vaporization of the prostate. Urol Clin North Am 2009;36:471-83.
17. Monoski MA, Gonzalez RR, Sandhu JS, Reddy B, Te AE. Urodynamic predictors of outcomes with photoselective laser vaporization prostatectomy in patients with benign prostatic hyperplasia and preoperative retention. Urology 2006;68:312-7.
18. Djavan B, Madenbacher S, Klingler C, Marberger M. Urodynamic assessment of patients with acute urinary retention: is treatment failure after prostatectomy predictable? J Urol 1997;158:1829-33.